Viracta Therapeutics, Inc.2024财年第三财季实现净利润-10.55百万美元，同比增加16.27%

市场透视11-16

11月16日，Viracta Therapeutics, Inc.（VIRX.US）公布财报，公告显示公司2024财年第三财季净利润为-10.55百万美元，同比增加16.27%；其中营业收入为0.00美元，每股基本收益为-0.27美元。从资产负债表来看，Viracta Therapeutics, Inc.（VIRX.US）总负债28.58百万美元，其中短期债务16.91百万美元，资产负债比为...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2483309890?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-16 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2483309890","market":"us","top_or_hot":-1,"title":"Viracta Therapeutics, Inc.2024财年第三财季实现净利润-10.55百万美元，同比增加16.27%","media":"市场透视","content":"<div>\n<p>11月16日，Viracta Therapeutics, Inc.（VIRX.US）公布财报，公告显示公司2024财年第三财季净利润为-10.55百万美元，同比增加16.27%；其中营业收入为0.00美元，每股基本收益为-0.27美元。从资产负债表来看，Viracta Therapeutics, Inc.（VIRX.US）总负债28.58百万美元，其中短期债务16.91百万美元，资产负债比为...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116000320a23b89e1&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Viracta Therapeutics, Inc.2024财年第三财季实现净利润-10.55百万美元，同比增加16.27%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nViracta Therapeutics, Inc.2024财年第三财季实现净利润-10.55百万美元，同比增加16.27%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-16 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116000320a23b89e1&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>11月16日，Viracta Therapeutics, Inc.（VIRX.US）公布财报，公告显示公司2024财年第三财季净利润为-10.55百万美元，同比增加16.27%；其中营业收入为0.00美元，每股基本收益为-0.27美元。从资产负债表来看，Viracta Therapeutics, Inc.（VIRX.US）总负债28.58百万美元，其中短期债务16.91百万美元，资产负债比为...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116000320a23b89e1&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116000320a23b89e1&s=b","article_id":"2483309890","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116000320a23b89e1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2483309890","pubTimestamp":1731686435,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"11月16日，Viracta Therapeutics, Inc.公布财报，公告显示公司2024财年第三财季净利润为-10.55百万美元，同比增加16.27%；其中营业收入为0.00美元，每股基本收益为-0.27美元。从资产负债表来看，Viracta Therapeutics, Inc.总负债28.58百万美元，其中短期债务16.91百万美元，资产负债比为0.77，流动比率为0.77。机构评级：截至2024年11月16日，当前有3家机构对Viracta Therapeutics, Inc.目标价做出预测，其中目标均价为2.83美元，其中最低目标价为2.00美元，最高目标价为3.50美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"LENZ":"Therapeutics","VIRX":"Viracta Therapeutics, Inc."},"translate_title":"Viracta Therapeutics, Inc. achieved net profit of-US $10.55 million in the third fiscal quarter of fiscal 2024, a year-on-year increase of 16.27%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"VIRX":1},"content_text":"11月16日，Viracta Therapeutics, Inc.（VIRX.US）公布财报，公告显示公司2024财年第三财季净利润为-10.55百万美元，同比增加16.27%；其中营业收入为0.00美元，每股基本收益为-0.27美元。从资产负债表来看，Viracta Therapeutics, Inc.（VIRX.US）总负债28.58百万美元，其中短期债务16.91百万美元，资产负债比为0.77，流动比率为0.77。机构评级：截至2024年11月16日，当前有3家机构对Viracta Therapeutics, Inc.目标价做出预测，其中目标均价为2.83美元，其中最低目标价为2.00美元，最高目标价为3.50美元。公司简介：Viracta Therapeutics Inc 是一家专注于开发针对与病毒相关恶性肿瘤的新药物的精准肿瘤学公司。该公司正在为其组合产品候选药物进行三项临床试验，作为治疗复发/难治性Epstein-Barr病毒阳性淋巴瘤的潜在疗法。该公司的产品候选药物是一种组合产品候选药物，由nanatinostat（一种强效且选择性的I类组蛋白去乙酰化酶（HDAC）小分子抑制剂）和valganciclovir（一种经FDA批准的抗病毒药物，用于治疗和预防器官移植中由巨细胞病毒（CMV）引起的疾病）组成。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483309890"}